|
 The total potential value of the collaboration, which will run for
three years, is up to $1 billion.
As part of the collaboration, Evotec will explore potential drug
candidates for the treatment of diabetes and chronic liver disease,
the Hamburg-based company said.
Eli Lilly has the right to select up to five programmes developed
within the partnership and then assume responsibility for further
development and commercialisation.
[to top of second column] |
 Evotec will receive an upfront
payment from the U.S. company, the amount of
which was not disclosed, and will receive
performance-based milestone payments of up to
$180 million per programme and royalties on any
products from the collaboration.
(Reporting by Patricia Weiss, Writing by Miranda
Murray; Editing by Paul Carrel)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
